The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
Keytruda could soon be approved in periadjuvant breast cancer, but adjuvant lung cancer, a bigger setting, is 2021’s big showdown.